600529.SS
Shandong Pharmaceutical Glass Co., Ltd [600529.SS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
600529.SS Stock Summary
Top 10 Correlated ETFs
600529.SS
Top 10 Correlated Stocks
600529.SS
In the News
600529.SS Financial details
Company Rating
Buy
Market Cap
17.45B
Income
681.91M
Revenue
4.63B
Book val./share
10.73
Cash/share
3.78
Dividend
0.3
Dividend %
1.08%
Employees
6.41K
Optionable
No
Shortable
Yes
Earnings
28 Apr 2022
P/E
27.2
Forward P/E
-
PEG
29.92
P/S
3.99
P/B
2.6
P/C
7.36
P/FCF
-984.05
Quick Ratio
2.33
Current Ratio
2.95
Debt / Equity
0
LT Debt / Equity
-
-
-
EPS (TTM)
1.08
EPS next Y
-
EPS next Q
-
EPS this Y
4.04%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
11.41%
Revenue last 5Y
10.13%
Revenue Q/Q
-4.11%
EPS Q/Q
32%
-
-
-
-
SMA20
6%
SMA50
-0.07%
SMA100
10.03%
Inst Own
-
Inst Trans
-
ROA
8%
ROE
10%
ROC
0.1%
Gross Margin
26%
Oper. Margin
15%
Profit Margin
15%
Payout
-
Shs Outstand
663.61M
Shs Float
532.16M
-
-
-
-
Target Price
-
52W Range
23.23-32.97
52W High
-13.09%
52W Low
+20.91%
RSI
69.68
Rel Volume
1.78
Avg Volume
4.62M
Volume
8.23M
Perf Week
6.67%
Perf Month
10.01%
Perf Quarter
7.96%
Perf Half Y
1.46%
-
-
-
-
Beta
0.542315
-
-
Volatility
0.77%, 1%
Prev Close
-0.96%
Price
27.81
Change
2.73%
600529.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 4.33 | 5.02 | 5.77 | 6.49 | 6.98 | |
| Net income per share | 0.6 | 0.77 | 0.95 | 0.99 | 1.03 | |
| Operating cash flow per share | 0.78 | 1.01 | 0.95 | 1.26 | 0.42 | |
| Free cash flow per share | 0.2 | 0.01 | 0.05 | -0.1 | -0.76 | |
| Cash per share | 1.4 | 2.55 | 2.29 | 2 | 4.09 | |
| Book value per share | 5.91 | 6.49 | 7.16 | 7.82 | 11.6 | |
| Tangible book value per share | 5.65 | 6.2 | 6.82 | 7.49 | 11.16 | |
| Share holders equity per share | 5.91 | 6.49 | 7.16 | 7.82 | 11.6 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 7.93B | 16.47B | 29.8B | 26.21B | 17.05B | |
| Enterprise value | 7.1B | 15.41B | 28.66B | 25.33B | 15.7B | |
| P/E ratio | 22.15 | 35.9 | 52.79 | 44.34 | 27.57 | |
| Price to sales ratio | 3.07 | 5.5 | 8.69 | 6.76 | 4.07 | |
| POCF ratio | 17.03 | 27.49 | 52.64 | 34.93 | 67.53 | |
| PFCF ratio | 67.02 | 2.24K | 967.07 | -445.64 | -37.2 | |
| P/B Ratio | 2.25 | 4.26 | 7 | 5.61 | 2.45 | |
| PTB ratio | 2.25 | 4.26 | 7 | 5.61 | 2.45 | |
| EV to sales | 2.75 | 5.15 | 8.36 | 6.54 | 3.75 | |
| Enterprise value over EBITDA | 11.52 | 21.26 | 31.14 | 26.23 | 15.06 | |
| EV to operating cash flow | 15.24 | 25.72 | 50.64 | 33.75 | 62.2 | |
| EV to free cash flow | 59.97 | 2.09K | 930.34 | -430.59 | -34.26 | |
| Earnings yield | 0.05 | 0.03 | 0.02 | 0.02 | 0.04 | |
| Free cash flow yield | 0.01 | 0 | 0 | 0 | -0.03 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | -1.35 | -1.46 | -1.23 | -0.92 | -1.29 | |
| Current ratio | 2.81 | 2.4 | 2.41 | 1.99 | 3.02 | |
| Interest coverage | -284.72 | -342.68 | -293.88 | -253.2 | -273.38 | |
| Income quality | 1.3 | 1.31 | 1 | 1.27 | 0.41 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | 0.28 | 0.28 | 0.32 | 0.3 | 0.29 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Research and developement to revenue | 0.03 | 0.04 | 0.04 | 0.04 | 0.03 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.04 | 0.03 | 0.03 | |
| Capex to operating cash flow | -0.75 | -0.99 | -0.95 | -1.08 | -2.82 | |
| Capex to revenue | -0.13 | -0.2 | -0.16 | -0.21 | -0.17 | |
| Capex to depreciation | -2.37 | -3.5 | -2.46 | -3.36 | -2.41 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 8.93 | 10.61 | 12.37 | 13.2 | 16.39 | |
| ROIC | 0.11 | 0.13 | 0.14 | 0.13 | 0.09 | |
| Return on tangible assets | 0.08 | 0.09 | 0.1 | 0.1 | 0.07 | |
| Graham Net | 1.04 | 1.91 | 1.93 | 1.41 | 4.1 | |
| Working capital | 1.93B | 1.75B | 1.84B | 1.66B | 3.56B | |
| Tangible asset value | 3.37B | 3.7B | 4.05B | 4.47B | 6.7B | |
| Net current asset value | 1.89B | 1.7B | 1.78B | 1.6B | 3.5B | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 778.62M | 784.12M | 902.18M | 1.15B | 1.45B | |
| Average payables | 758.01M | 899.05M | 995.98M | 1.22B | 1.43B | |
| Average inventory | 558.27M | 625.31M | 714.28M | 813.47M | 1.04B | |
| Days sales outstanding | 112.24 | 94.34 | 109.8 | 119.17 | 142.06 | |
| Days payables outstanding | 176.92 | 192.59 | 159.62 | 192.12 | 168.95 | |
| Days of inventory on hand | 126.03 | 131.34 | 120.09 | 117.46 | 144.17 | |
| Receivables turnover | 3.25 | 3.87 | 3.32 | 3.06 | 2.57 | |
| Payables turnover | 2.06 | 1.9 | 2.29 | 1.9 | 2.16 | |
| Inventory turnover | 2.9 | 2.78 | 3.04 | 3.11 | 2.53 | |
| ROE | 0.1 | 0.12 | 0.13 | 0.13 | 0.09 | |
| Capex per share | -0.58 | -0.99 | -0.9 | -1.36 | -1.18 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.59 | 1.72 | 2 | 1.86 | 1.78 | |
| Net income per share | 0.29 | 0.29 | 0.21 | 0.25 | 0.33 | |
| Operating cash flow per share | 0.29 | 0.29 | 0.21 | 0.25 | 0.31 | |
| Free cash flow per share | 0.02 | -0.05 | 0.02 | 0.05 | -0.06 | |
| Cash per share | 1.57 | 1.11 | 4.09 | 3.79 | 3.78 | |
| Book value per share | 8.18 | 8.48 | 11.6 | 10.7 | 10.73 | |
| Tangible book value per share | 7.73 | 8.03 | 11.16 | 10.31 | 10.34 | |
| Share holders equity per share | 8.18 | 8.48 | 11.6 | 10.7 | 10.73 | |
| Interest debt per share | 0.01 | 0.07 | 0.02 | 0.01 | 0.02 | |
| Market cap | 16.47B | 17.07B | 17.05B | 17.48B | 18.13B | |
| Enterprise value | 15.68B | 16.46B | 15.7B | 16.11B | 17.18B | |
| P/E ratio | 24.41 | 24.68 | 34.51 | 26.25 | 20.7 | |
| Price to sales ratio | 17.63 | 16.87 | 14.22 | 14.14 | 15.29 | |
| POCF ratio | 97.64 | 98.72 | 138.06 | 105 | 88.15 | |
| PFCF ratio | 1.45K | -580.83 | 1.14K | 520.19 | -478.09 | |
| P/B Ratio | 3.42 | 3.42 | 2.45 | 2.45 | 2.54 | |
| PTB ratio | 3.42 | 3.42 | 2.45 | 2.45 | 2.54 | |
| EV to sales | 16.78 | 16.26 | 13.1 | 13.03 | 14.49 | |
| Enterprise value over EBITDA | 85.32 | 111.62 | 78 | 84.44 | 61.83 | |
| EV to operating cash flow | 92.97 | 95.19 | 127.15 | 96.76 | 83.53 | |
| EV to free cash flow | 1.38K | -560.04 | 1.05K | 479.37 | -453.04 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | -4.28 | -4.14 | -6.69 | -7.19 | -3.42 | |
| Current ratio | 1.93 | 2 | 3.02 | 3.12 | 2.95 | |
| Interest coverage | 51.01 | 2.46 | 22.94 | -317.77 | 0 | |
| Income quality | 1 | 1 | 1 | 1 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | -0.03 | 0.1 | -0.08 | 0.03 | -0.02 | |
| Research and developement to revenue | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Intangibles to total assets | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | |
| Capex to operating cash flow | -0.93 | -1.17 | -0.88 | -0.8 | -1.18 | |
| Capex to revenue | -0.17 | -0.2 | -0.09 | -0.11 | -0.21 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 7.26 | 7.48 | 7.33 | 7.76 | 8.91 | |
| ROIC | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 | |
| Return on tangible assets | 0.03 | 0.03 | 0.01 | 0.02 | 0.02 | |
| Graham Net | 1.17 | 1.07 | 4.1 | 3.94 | 3.8 | |
| Working capital | 1.67B | 1.67B | 3.56B | 3.7B | 3.63B | |
| Tangible asset value | 4.56B | 4.73B | 6.7B | 6.87B | 6.89B | |
| Net current asset value | 1.61B | 1.61B | 3.5B | 3.65B | 3.58B | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 1.42B | 1.46B | 1.56B | 1.7B | 1.8B | |
| Average payables | 1.34B | 1.37B | 1.41B | 1.39B | 1.32B | |
| Average inventory | 1.03B | 1.15B | 1.2B | 1.18B | 1.15B | |
| Days sales outstanding | 138.2 | 132.28 | 122.37 | 128.65 | 138.41 | |
| Days payables outstanding | 181.14 | 170.61 | 137.92 | 130.45 | 139.41 | |
| Days of inventory on hand | 150.92 | 145.69 | 117.69 | 109.59 | 124.46 | |
| Receivables turnover | 0.65 | 0.68 | 0.74 | 0.7 | 0.65 | |
| Payables turnover | 0.5 | 0.53 | 0.65 | 0.69 | 0.65 | |
| Inventory turnover | 0.6 | 0.62 | 0.76 | 0.82 | 0.72 | |
| ROE | 0.04 | 0.03 | 0.02 | 0.02 | 0.03 | |
| Capex per share | -0.27 | -0.34 | -0.18 | -0.2 | -0.37 |
600529.SS Frequently Asked Questions
What is Shandong Pharmaceutical Glass Co., Ltd stock symbol ?
Shandong Pharmaceutical Glass Co., Ltd is a CN stock and trading under the symbol 600529.SS
What is Shandong Pharmaceutical Glass Co., Ltd stock quote today ?
Shandong Pharmaceutical Glass Co., Ltd stock price is $27.81 today.
Is Shandong Pharmaceutical Glass Co., Ltd stock public?
Yes, Shandong Pharmaceutical Glass Co., Ltd is a publicly traded company.
Company Profile
- Volume Average 4.62M
- Market Capitalization 17.45B
- Employee 6.41K
- CEO Mr. Jun Zhang
- Headquarters Zibo,CN
- IPO Date 2002-06-03
-
Website
https://www.pharmglass.com 
Shandong Pharmaceutical Glass Co., Ltd manufactures and sells pharmaceutical glass packaging and butyl rubber series products in China. It offers pharma glass packaging products, such as molded injection glass vials, food-grade bottles, clear cosmetic bottles, cobalt blue and green bottles, tubular glass vials, ampoules, glass tubing products, amber glass bottles, and other borosilicate glass products; butyl rubber stoppers; prefilled syringes, plastic and aluminum caps, plastic caps, and plastic bottles; and dropper caps and Teflon coated rubber stoppers. The company sells its products to the pharmaceutical, food, and cosmetic glass packaging industries. It also exports its products to Europe, the United States, Russia, Japan, Korea, Southeast Asia, and other countries. Shandong Pharmaceutical Glass Co., Ltd was founded in 1970 and is based in Zibo, China.
